Pyxis Oncology, Inc. Common Stock
$3.33
-$0.08 (-2.35%)
$3.33Day Range$3.44
Key Statistics
Market Cap
$284.42M
Shares Outstanding
83.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 8, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$3.38
Day High
$3.44
Day Low
$3.33
Volume
561.0K
VWAP
$3.35
Prev Close
$3.41
Transactions
--
Acc. Volume
--
About Pyxis Oncology, Inc. Common Stock
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
PHARMACEUTICAL PREPARATIONSSIC 283456 employees321 HARRISON AVENUE, BOSTON, MA, 02118(617) 221-9059IPO Oct 8, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001782223
- Composite FIGI
- BBG00PQFFCV5
- Share Class FIGI
- BBG00PQFFCW4
- Ticker Root
- PYXS
- SIC Code
- 2834
About Pyxis Oncology, Inc. Common Stock (PYXS) Stock
Pyxis Oncology, Inc. Common Stock (PYXS) closed the 2026-09-18 session at $3.33, down 2.35% versus the previous close (-0.08). The stock opened at $3.38 and traded between $3.33 and $3.44 during that session. Session trading volume was 561K shares. The volume-weighted average price (VWAP) is $3.35.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Pyxis Oncology, Inc. Common Stock has a market capitalization of $284.4 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. PYXS is listed on the XNAS exchange. The company employs approximately 56 people. Pyxis Oncology, Inc. Common Stock is headquartered in BOSTON, MA. The recorded listing date is 2021-10-08.
On this page you can find market PYXS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.